
## Jeong-Hoon Lee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2545486/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Prognostic Prediction Model of Transarterial Radioembolization in Hepatocellular Carcinoma: SNAP-HCC. Digestive Diseases and Sciences, 2022, 67, 329-336.	1.1	5
2	Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B. Clinical Gastroenterology and Hepatology, 2022, 20, 1343-1353.e16.	2.4	9
3	An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. Journal of Hepatology, 2022, 76, 311-318.	1.8	48
4	Comparison of biochemical response during antiviral treatment in patients with chronic hepatitis B infection. Liver International, 2022, 42, 320-329.	1.9	7
5	Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis. Hepatology, 2022, 76, 492-501.	3.6	26
6	Long-Term Outcomes of Transarterial Radioembolization for Large Single Hepatocellular Carcinoma: A Comparison to Resection. Journal of Nuclear Medicine, 2022, 63, 1215-1222.	2.8	12
7	Prognostic Values of Inflammation-Based Scores and Fibrosis Markers in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. Diagnostics, 2022, 12, 1170.	1.3	7
8	Association of Chronic Hepatitis B Infection and Antiviral Treatment With the Development of the Extrahepatic Malignancies: A Nationwide Cohort Study. Journal of Clinical Oncology, 2022, 40, 3394-3405.	0.8	6
9	Quantitative Assessment of Fatty Liver using Ultrasound withÂNormalized Local Variance Technique. Ultraschall in Der Medizin, 2021, 42, 599-606.	0.8	9
10	Empirical Treatment With Carbapenem vs Third-generation Cephalosporin for Treatment of Spontaneous Bacterial Peritonitis. Clinical Gastroenterology and Hepatology, 2021, 19, 976-986.e5.	2.4	13
11	Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib. Clinical Cancer Research, 2021, 27, 713-718.	3.2	27
12	Association of Metabolic Risk Factors With Risks of Cancer and Allâ€Cause Mortality in Patients With Chronic Hepatitis B. Hepatology, 2021, 73, 2266-2277.	3.6	45
13	Radiofrequency Ablation Using a Separable Clustered Electrode for the Treatment of Hepatocellular Carcinomas: A Randomized Controlled Trial of a Dual-Switching Monopolar Mode Versus a Single-Switching Monopolar Mode. Korean Journal of Radiology, 2021, 22, 179.	1.5	8
14	Distinctive HBV Replication Capacity and Susceptibility to Tenofovir Induced by a Polymerase Point Mutation in Hepatoma Cell Lines and Primary Human Hepatocytes. International Journal of Molecular Sciences, 2021, 22, 1606.	1.8	3
15	Hepatocellular Carcinoma in Korea: an Analysis of the 2015 Korean Nationwide Cancer Registry. Journal of Liver Cancer, 2021, 21, 58-70.	0.3	18
16	Effectiveness of Transarterial Chemoembolization-First Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 587-598.	1.8	1
17	Inclusive Quantification Assay of Serum Desâ€î³â€Carboxyprothrombin Proteoforms for Hepatocellular Carcinoma Surveillance by Targeted Mass Spectrometry. Hepatology Communications, 2021, 5, 1767-1783.	2.0	4
18	Efficacy of entecavir versus tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response. Journal of Viral Hepatitis, 2021, 28, 1392-1399.	1.0	13

#	Article	IF	CITATIONS
19	Systems analysis identifies endothelin 1 axis blockade for enhancing the anti-tumor effect of multikinase inhibitor. Cancer Gene Therapy, 2021, , .	2.2	4
20	Update on liver disease management during the pandemic of coronavirus disease 2019 (COVID-19): 2021 KASL guideline. Clinical and Molecular Hepatology, 2021, 27, 515-523.	4.5	6
21	Old hepatitis B virus never dies: It just hides itself within the host genome. Clinical and Molecular Hepatology, 2021, 27, 107-109.	4.5	3
22	Switching Monopolar No-Touch Radiofrequency Ablation Using Octopus Electrodes for Small Hepatocellular Carcinoma: A Randomized Clinical Trial. Liver Cancer, 2021, 10, 72-81.	4.2	19
23	No-Touch vs. Conventional Radiofrequency Ablation Using Twin Internally Cooled Wet Electrodes for Small Hepatocellular Carcinomas: A Randomized Prospective Comparative Study. Korean Journal of Radiology, 2021, 22, 1974.	1.5	18
24	Comparison of Overall Survival between Surgical Resection and Radiofrequency Ablation for Hepatitis B-Related Hepatocellular Carcinoma. Cancers, 2021, 13, 6009.	1.7	9
25	Cost-Effectiveness of Adjuvant Immunotherapy With Cytokine-Induced Killer Cell for Hepatocellular Carcinoma Based on a Randomized Controlled Trial and Real-World Data. Frontiers in Oncology, 2021, 11, 728740.	1.3	4
26	Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1565-1577.	1.8	12
27	The Model to Estimate Survival in Ambulatory Hepatocellular Carcinoma Patients Aids in the Decision for TACE Retreatment. Journal of Clinical Gastroenterology, 2020, 54, 370-377.	1.1	Ο
28	Novel Model to Predict HCC Recurrence after Liver Transplantation Obtained Using Deep Learning: A Multicenter Study. Cancers, 2020, 12, 2791.	1.7	25
29	Effect of urea cream on sorafenib-associated hand–foot skin reaction in patients with hepatocellular carcinoma: A multicenter, randomised, double-blind controlled study. European Journal of Cancer, 2020, 140, 19-27.	1.3	13
30	Survival of oral mucosal melanoma according to treatment, tumour resection margin, and metastases. British Journal of Oral and Maxillofacial Surgery, 2020, 58, 1097-1102.	0.4	12
31	How to Best Detect Portal Vein Tumor Thrombosis in Patients with Hepatocellular Carcinoma Meeting the Milan Criteria: Gadoxetic Acid-Enhanced MRI versus Contrast-Enhanced CT. Liver Cancer, 2020, 9, 293-307.	4.2	24
32	Risk of Liver Cirrhosis and Hepatocellular Carcinoma after Fontan Operation: A Need for Surveillance. Cancers, 2020, 12, 1805.	1.7	23
33	Distinctive patterns of pulmonary function change according to baseline lung volume and diffusing capacity. International Journal of Tuberculosis and Lung Disease, 2020, 24, 597-605.	0.6	4
34	Prognosis predictability of serum and urine renal markers in patients with decompensated cirrhosis: A multicentre prospective study. Liver International, 2020, 40, 3083-3092.	1.9	11
35	Direct-Acting Antivirals Improve Treatment Outcomes in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Nationwide, Multi-center, Retrospective Cohort Study. Digestive Diseases and Sciences, 2020, 66, 2427-2438.	1.1	3
36	Combination of 1 <sup>st</sup> and 2 <sup>nd</sup> Week Dosing of Glass Yttrium-90 Microspheres for Superselective Radioembolization. In Vivo, 2020, 34, 2763-2768.	0.6	4

#	Article	IF	CITATIONS
37	Tivozanib in advanced inoperable hepatocellular carcinoma: considerations for patients with liver cirrhosis. Annals of Translational Medicine, 2020, 8, 1530-1530.	0.7	0
38	CKD-5, a novel pan-histone deacetylase inhibitor, synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma. BMC Cancer, 2020, 20, 1001.	1.1	4
39	A differential risk assessment and decision model for Transarterial chemoembolization in hepatocellular carcinoma based on hepatic function. BMC Cancer, 2020, 20, 504.	1.1	17
40	Entecavir Plus Pegylated Interferon and Sequential Hepatitis B Virus Vaccination Increases Hepatitis B Surface Antigen Seroclearance: A Randomized Controlled Proof-of-Concept Study. Clinical Infectious Diseases, 2020, 73, e3308-e3316.	2.9	12
41	Proteome Multimarker Panel With Multiple Reaction Monitoring–Mass Spectrometry for Early Detection of Hepatocellular Carcinoma. Hepatology Communications, 2020, 4, 753-768.	2.0	3
42	Entecavirâ€resistant hepatitis B virus decreases surface antigenicity: A full genome and functional characterization. Liver International, 2020, 40, 1564-1577.	1.9	4
43	Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study. Gut, 2020, 69, 2214-2222.	6.1	20
44	Prognostic impact of concurrent nonalcoholic fatty liver disease in patients with chronic hepatitis Bâ€related hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1960-1968.	1.4	13
45	Evaluation of a serum tumour markerâ€based recurrence prediction model after radiofrequency ablation for hepatocellular carcinoma. Liver International, 2020, 40, 1189-1200.	1.9	20
46	Myocardial structural and functional changes in patients with liver cirrhosis awaiting liver transplantation: a comprehensive cardiovascular magnetic resonance and echocardiographic study. Journal of Cardiovascular Magnetic Resonance, 2020, 22, 25.	1.6	23
47	Radiofrequency ablation using internally cooled wet electrodes in bipolar mode for the treatment of recurrent hepatocellular carcinoma after locoregional treatment: A randomized prospective comparative study. PLoS ONE, 2020, 15, e0239733.	1.1	8
48	Hepatocellular Carcinoma in Korea Between 2008 and 2011: an Analysis of Korean Nationwide Cancer Registry. Journal of Liver Cancer, 2020, 20, 41-52.	0.3	15
49	Hepatocellular Carcinoma in Korea between 2012 and 2014: an Analysis of Data from the Korean Nationwide Cancer Registry. Journal of Liver Cancer, 2020, 20, 135-147.	0.3	15
50	Two-Dimensional-Shear Wave Elastography with a Propagation Map: Prospective Evaluation of Liver Fibrosis Using Histopathology as the Reference Standard. Korean Journal of Radiology, 2020, 21, 1317.	1.5	12
51	Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment. Clinical and Molecular Hepatology, 2020, 26, 328-339.	4.5	32
52	Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop. Clinical and Molecular Hepatology, 2020, 26, 411-429.	4.5	66
53	Management of liver diseases during the pandemic of coronavirus disease-19. Clinical and Molecular Hepatology, 2020, 26, 243-250.	4.5	8
54	Long-term Nucleotide Analogue Treatment Has Higher Levels of Renal Toxicities than Does Entecavir in Patients with Chronic Hepatitis B. Gut and Liver, 2020, 14, 225-231.	1.4	2

#	Article	IF	CITATIONS
55	The Impact of National Surveillance for Liver Cancer: Results from Real-World Setting in Korea. Gut and Liver, 2020, 14, 108-116.	1.4	16
56	Proposal of a New Risk Score for Patients Treated with Transarterial Chemoembolization due to Recurrent Hepatocellular Carcinoma after Curative Resection: A Multicenter Study. Gut and Liver, 2020, 14, 477-485.	1.4	1
57	Child-Pugh B or C Cirrhosis Increases the Risk for Bleeding Following Colonoscopic Polypectomy. Gut and Liver, 2020, 14, 755-764.	1.4	17
58	Appraisal of a Model to Estimate Survival in Ambulatory Patients with Hepatocellular Carcinoma Classified as Barcelona Clinic Liver Cancer Stage B. Gut and Liver, 2020, 14, 377-386.	1.4	1
59	Optimal Modalities for HCC Surveillance in a Highâ€Incidence Region. Clinical Liver Disease, 2020, 16, 236-239.	1.0	2
60	Effectiveness of drug-eluting bead transarterial chemoembolization versus conventional transarterial chemoembolization for small hepatocellular carcinoma in Child-Pugh class A patients. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591986607.	1.4	21
61	Cone-Beam CT–Guided Chemoembolization in Patients with Complete Response after Previous Chemoembolization but Subsequent Elevated α-Fetoprotein without Overt Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2019, 30, 1273-1280.	0.2	7
62	Tumor Marker-Based Definition of the Transarterial Chemoembolization-Refractoriness in Intermediate-Stage Hepatocellular Carcinoma: A Multi-Cohort Study. Cancers, 2019, 11, 1721.	1.7	8
63	Nonalcoholic fatty liver disease is an early predictor of metabolic diseases in a metabolically healthy population. PLoS ONE, 2019, 14, e0224626.	1.1	27
64	Comparison of Models for Tumor Recurrence after Liver Transplantation for the Patients with Hepatocellular Carcinoma: A Multicenter Long-Term Follow-Up Study. Cancers, 2019, 11, 1295.	1.7	11
65	Adjuvant cytokine-induced killer cell immunotherapy for hepatocellular carcinoma: a propensity score-matched analysis of real-world data. BMC Cancer, 2019, 19, 523.	1.1	24
66	Assessment of hepatic steatosis by using attenuation imaging: a quantitative, easy-to-perform ultrasound technique. European Radiology, 2019, 29, 6499-6507.	2.3	104
67	Additional fibrate treatment in UDCAâ€refractory PBC patients. Liver International, 2019, 39, 1776-1785.	1.9	24
68	Hexokinase-II Inhibition Synergistically Augments the Anti-tumor Efficacy of Sorafenib in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2019, 20, 1292.	1.8	32
69	Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients. Journal of Hepatology, 2019, 70, 1093-1102.	1.8	107
70	Carbonic anhydrase-IX inhibition enhances the efficacy of hexokinase II inhibitor for hepatocellular carcinoma in a murine model. Journal of Bioenergetics and Biomembranes, 2019, 51, 121-129.	1.0	7
71	Reply to: "In response to identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients.â€: Journal of Hepatology, 2019, 71, 1260-1261.	1.8	Ο
72	A Model to Predict 1â€Month Risk of Transplant or Death in Hepatitis A–Related Acute Liver Failure. Hepatology, 2019, 70, 621-629.	3.6	23

#	Article	IF	CITATIONS
73	Non-hypervascular hepatobiliary phase hypointense nodules on gadoxetic acid-enhanced MR can help determine the treatment method for HCC. European Radiology, 2019, 29, 3122-3131.	2.3	17
74	Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up. Cancer Immunology, Immunotherapy, 2019, 68, 23-32.	2.0	62
75	Feasibility of Boosted Radioembolization for Hepatocellular Carcinoma Larger than 5 cm. Journal of Vascular and Interventional Radiology, 2019, 30, 1-8.	0.2	26
76	Identification of additional EHMT2 variant associated with the risk of chronic hepatitis B by GWAS follow-up study. Genes and Immunity, 2019, 20, 1-9.	2.2	13
77	Comparison of four different Shear Wave Elastography platforms according to abdominal wall thickness in liver fibrosis evaluation: a phantom study. Medical Ultrasonography, 2019, 21, 22.	0.4	15
78	Tenofovir and Entecavir Have Similar Renal Adverse Events on Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization. Journal of Liver Cancer, 2019, 19, 128-135.	0.3	1
79	Novel Albumin–Bilirubin Grade-Based Risk Prediction Model for Patients with Hepatocellular Carcinoma Undergoing Chemoembolization. Digestive Diseases and Sciences, 2018, 63, 1062-1071.	1.1	23
80	Prognostic Role of Liver Stiffness Measurements Using Magnetic Resonance Elastography in Patients with Compensated Chronic Liver Disease. European Radiology, 2018, 28, 3513-3521.	2.3	24
81	Liver Stiffness Measured by Two-Dimensional Shear-Wave Elastography: Prognostic Value after Radiofrequency Ablation for Hepatocellular Carcinoma. Liver Cancer, 2018, 7, 65-75.	4.2	23
82	Intensity of surveillance for hepatocellular carcinoma determines survival in patients at risk in a hepatitis Bâ€endemic area. Alimentary Pharmacology and Therapeutics, 2018, 47, 1490-1501.	1.9	22
83	The relationship between clinical characteristics including presence of exposed lesions and healthâ€related quality of life (HRQoL) in patients with psoriasis: analysis from the nationwide epidemiologic study for psoriasis in Korea (EPIâ€PSODE study). Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1499-1506.	1.3	9
84	A Model for Adaptive Decision Making of "Ablate-and-Wait―Versus Transplantation in Patients With Hepatocellular Carcinoma. Journal of Clinical Gastroenterology, 2018, 52, 655-661.	1.1	1
85	Entecavir and tenofovir reduce hepatitis B virusâ€related hepatocellular carcinoma recurrence more effectively than other antivirals. Journal of Viral Hepatitis, 2018, 25, 707-717.	1.0	23
86	Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study. BMC Cancer, 2018, 18, 307.	1.1	18
87	Nonalcoholic fatty liver disease and advanced fibrosis are associated with left ventricular diastolic dysfunction. Atherosclerosis, 2018, 272, 137-144.	0.4	38
88	Suppression of interferon-mediated anti-HBV response by single CpG methylation in the 5′-UTR of <i>TRIM22</i> . Gut, 2018, 67, 166-178.	6.1	56
89	Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in <scp>HB</scp> eAgâ€positive high viral load chronic hepatitis B. Journal of Viral Hepatitis, 2018, 25, 552-560.	1.0	11
90	The effect of 6% hydroxyethyl starch (130/0.4) on acute kidney injury in paediatric cardiac surgery: a prospective, randomised trial. Anaesthesia, 2018, 73, 205-215.	1.8	17

#	Article	IF	CITATIONS
91	Chemoembolisation for hepatocellular carcinoma with bile duct invasion: is preprocedural biliary drainage mandatory?. European Radiology, 2018, 28, 1540-1550.	2.3	6
92	Initial Alpha-Fetoprotein Response Predicts Prognosis in Hepatitis B-related Solitary HCC Patients After Radiofrequency Ablation. Journal of Clinical Gastroenterology, 2018, 52, e18-e26.	1.1	13
93	Is Combination Antiviral Therapy Mandatory for Maintenance Therapy in Fully Suppressed Multidrug-Resistant Hepatitis B Patients?. Gastroenterology Research and Practice, 2018, 2018, 1-9.	0.7	1
94	Analysis of significant protein abundance from multiple reaction-monitoring data. BMC Systems Biology, 2018, 12, 123.	3.0	0
95	Efficacy of Sorafenib for the Treatment of Post-Transplant Hepatocellular Carcinoma Recurrence. Journal of Korean Medical Science, 2018, 33, e283.	1.1	21
96	Differential Effect of HCV Eradication and Fibrosis Grade on Hepatocellular Carcinoma and All-cause Mortality. Scientific Reports, 2018, 8, 13651.	1.6	7
97	Seldinger vs modified Seldinger techniques for ultrasound-guided central venous catheterisation inÂneonates: a randomised controlled trial. British Journal of Anaesthesia, 2018, 121, 1332-1337.	1.5	18
98	Synergistic effect of ursodeoxycholic acid on the antitumor activity of sorafenib in hepatocellular carcinoma cells via modulation of STAT3 and ERK. International Journal of Molecular Medicine, 2018, 42, 2551-2559.	1.8	12
99	Flexion decreases the ventilation quality of the Ambu <sup>®</sup> AuraGainâ,"¢ laryngeal mask in paralysed children: A prospective randomised crossover study. Acta Anaesthesiologica Scandinavica, 2018, 62, 1080-1085.	0.7	9
100	Editorial: frequency of surveillance and survival in hepatocellular carcinoma—authors' reply. Alimentary Pharmacology and Therapeutics, 2018, 48, 229-230.	1.9	0
101	Reply. Hepatology, 2018, 67, 1643-1644.	3.6	0
102	Comparison of overall survival between antiviralâ€induced viral suppression and inactive phase chronic hepatitis B patients. Journal of Viral Hepatitis, 2018, 25, 1161-1171.	1.0	18
103	Scoring system for risk stratification of viral reactivation during prophylactic antiviral treatment in Korean patients with hepatitis B undergoing anticancer chemotherapy: A multicenter study. Journal of Medical Virology, 2018, 90, 1593-1603.	2.5	6
104	Sustained efficacy of adjuvant immunotherapy with cytokineinduced killer cells for hepatocellular carcinoma: an extended 5-year follow-up. Journal of Hepatology, 2018, 68, S37-S38.	1.8	6
105	Cirrhotic cardiomyopathy: An independent prognostic factor for cirrhotic patients. Clinical and Molecular Hepatology, 2018, 24, 372-373.	4.5	4
106	Sub-classification of Advanced-Stage Hepatocellular Carcinoma: A Cohort Study Including 612 Patients Treated with Sorafenib. Cancer Research and Treatment, 2018, 50, 366-373.	1.3	15
107	Direct Detection of Drug-Resistant Hepatitis B Virus in Serum Using a Dendron-Modified Microarray. Gut and Liver, 2018, 12, 331-341.	1.4	4
108	Targeted Proteomics Predicts a Sustained Complete-Response after Transarterial Chemoembolization and Clinical Outcomes in Patients with Hepatocellular Carcinoma: A Prospective Cohort Study. Journal of Proteome Research, 2017, 16, 1239-1248.	1.8	27

#	Article	IF	CITATIONS
109	Synergistic effect of cytokine-induced killer cell with valproate inhibits growth of hepatocellular carcinoma cell in a mouse model. Cancer Biology and Therapy, 2017, 18, 67-75.	1.5	13
110	Discrepancies between the percentage of plasma cells in bone marrow aspiration and BM biopsy: Impact on the revised IMWG diagnostic criteria of multiple myeloma. Blood Cancer Journal, 2017, 7, e530-e530.	2.8	33
111	Protein disulfide isomerase inhibition synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma. Hepatology, 2017, 66, 855-868.	3.6	35
112	Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment. Hepatology, 2017, 66, 1556-1569.	3.6	92
113	Adjuvant immunotherapy with autologous dendritic cells for hepatocellular carcinoma, randomized phase II study. Oncolmmunology, 2017, 6, e1328335.	2.1	38
114	Rifaximin reduces cirrhotic complications and prolongs overall survival in patients experiencing hepatic encephalopathy. Journal of Hepatology, 2017, 66, S572-S573.	1.8	1
115	Cone Beam CT–Guided Chemoembolization of Probable Hepatocellular Carcinomas Smaller than 1 cm in Patients at High Risk of Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2017, 28, 795-803.e1.	0.2	12
116	Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen–Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study. Journal of Infectious Diseases, 2017, 216, 1407-1414.	1.9	33
117	Integrative analysis of genomic and epigenomic regulation of the transcriptome in liver cancer. Nature Communications, 2017, 8, 839.	5.8	107
118	Realâ€ŧime ultrasoundâ€guided axillary vein cannulation in children: a randomised controlled trial. Anaesthesia, 2017, 72, 1516-1522.	1.8	11
119	Editorial: rifaximin in cirrhosis—is this what we've been waiting for? Authors' reply. Alimentary Pharmacology and Therapeutics, 2017, 46, 1017-1018.	1.9	1
120	Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy. Alimentary Pharmacology and Therapeutics, 2017, 46, 845-855.	1.9	73
121	A model to estimate survival in ambulatory patients with hepatocellular carcinoma: Can it predict the natural course of hepatocellular carcinoma?. Digestive and Liver Disease, 2017, 49, 1273-1279.	0.4	5
122	Integrated analysis of genomic and epigenomic regulation of transcriptome identifies molecular subtypes of liver cancer. Journal of Hepatology, 2017, 66, S639-S640.	1.8	2
123	Assessment of dynamic variables of fluid responsiveness to predict desufflation-induced hypotension during paediatric laparoscopic surgery. British Journal of Anaesthesia, 2017, 119, 956-963.	1.5	2
124	Incomplete biochemical response increases the risk of hepatocellular carcinoma in patients with suppressed chronic hepatitis B. Journal of Hepatology, 2017, 66, S476.	1.8	0
125	Predictor of fluid responsiveness in the â€~grey zone': augmented pulse pressure variation through a temporary increase in tidal volume. British Journal of Anaesthesia, 2017, 119, 50-56.	1.5	26
126	Effects of an alveolar recruitment manoeuvre guided by lung ultrasound on anaesthesiaâ€induced atelectasis in infants: a randomised, controlled trial. Anaesthesia, 2017, 72, 214-222.	1.8	76

#	Article	IF	CITATIONS
127	Optimal maintenance treatment with calcipotriol/betamethasone dipropionate gel in Korean patients with psoriasis vulgaris: a multicentre randomized, controlled clinical trial. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 483-489.	1.3	8
128	Transarterial chemoembolization of hepatocellular carcinoma with segmental portal vein tumour thrombus. European Radiology, 2017, 27, 1448-1458.	2.3	31
129	Hepatic stiffness measurement by using MR elastography: prognostic values after hepatic resection for hepatocellular carcinoma. European Radiology, 2017, 27, 1713-1721.	2.3	41
130	Identification of novel <i><scp>OCT</scp>4</i> genetic variant associated with the risk of chronic hepatitis B in a Korean population. Liver International, 2017, 37, 354-361.	1.9	13
131	Real-time US-CT/MR fusion imaging for percutaneous radiofrequency ablation of hepatocellular carcinoma. Journal of Hepatology, 2017, 66, 347-354.	1.8	103
132	Oral Medications Enhance Adherence to Surveillance for Hepatocellular Carcinoma and Survival in Chronic Hepatitis B Patients. PLoS ONE, 2017, 12, e0166188.	1.1	8
133	Validation of a Modified Child-Turcotte-Pugh Classification System Utilizing Insulin-Like Growth Factor-1 for Patients with Hepatocellular Carcinoma in an HBV Endemic Area. PLoS ONE, 2017, 12, e0170394.	1.1	11
134	Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naÃ <sup>-</sup> ve patients. Clinical and Molecular Hepatology, 2017, 23, 66-73.	4.5	13
135	Percutaneous Dual-Switching Monopolar Radiofrequency Ablation Using a Separable Clustered Electrode: A Preliminary Study. Korean Journal of Radiology, 2017, 18, 799.	1.5	12
136	Ultrasound-guided percutaneous portal transplantation of peripheral blood monocytes in patients with liver cirrhosis. Korean Journal of Internal Medicine, 2017, 32, 261-268.	0.7	8
137	A Novel Model for Predicting Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B and Normal Alanine Aminotransferase Levels. Gut and Liver, 2017, 11, 528-534.	1.4	22
138	Cytokine-Induced Killer Cells for the Adjuvant Treatment of Patients with HCC. , 2017, , 69-84.		0
139	Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria. Oncotarget, 2017, 8, 47555-47564.	0.8	1
140	ls tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis B virus?. Clinical and Molecular Hepatology, 2017, 23, 219-221.	4.5	3
141	Is it possible to predict the development of an entecavir resistance mutation in patients with chronic hepatitis B in clinical practice?. Clinical and Molecular Hepatology, 2017, 23, 311-313.	4.5	0
142	Modified AS1411 Aptamer Suppresses Hepatocellular Carcinoma by Up-Regulating Galectin-14. PLoS ONE, 2016, 11, e0160822.	1.1	38
143	Subclinical Ascites Does Not Affect the Long-term Prognosis in Hepatitis B Virus–related Cirrhosis Patients Receiving Antivirals. Journal of Clinical Gastroenterology, 2016, 50, 676-685.	1.1	1
144	High titers of antiâ€HBs prevent rituximabâ€related viral reactivation in resolved hepatitis B patient with nonâ€Hodgkin's lymphoma. Journal of Medical Virology, 2016, 88, 1010-1017.	2.5	50

#	Article	IF	CITATIONS
145	The Validation of a Newly Updated Child-Turcotte-Pugh Core Using Insulin Growth Factor-1 for Predicting Survival of Patients with Hepatocellular Carcinoma in Chronic Hepatitis B Endemic Area. Journal of Hepatology, 2016, 64, S325.	1.8	0
146	Comparison of Treatment Outcome between Living Donor Liver Transplantation and Sorafenib for Patients with BCLC B or C Stage Hepatocellular Carcinoma. Journal of Hepatology, 2016, 64, S553-S554.	1.8	0
147	Nucleos(T)Ide Analogue Treatment for Immune Tolerant Phase of Chronic Hepatitis B Patients Prolongs Overall Survival and Reduces the Risk of Hepatocellular Carcinoma and Cirrhosis: A Real-Life Study. Journal of Hepatology, 2016, 64, S162.	1.8	0
148	Targeted Proteomics Predicts Sustained Complete Response after Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma. Journal of Hepatology, 2016, 64, S702.	1.8	0
149	Edn1 Expression as a Novel Biomarker for Predicting Sorafenib Responsiveness in Patients with Hepatocellular Carcinoma. Journal of Hepatology, 2016, 64, S194.	1.8	Ο
150	Fucoidan-induced ID-1 suppression inhibits the in vitro and in vivo invasion of hepatocellular carcinoma cells. Biomedicine and Pharmacotherapy, 2016, 83, 607-616.	2.5	30
151	Differential sensitivity of hepatocellular carcinoma cells to suppression of hepatocystin transcription under hypoxic conditions. Journal of Bioenergetics and Biomembranes, 2016, 48, 581-590.	1.0	4
152	Effect of early vs. late tracheostomy on clinical outcomes in critically ill pediatric patients. Acta Anaesthesiologica Scandinavica, 2016, 60, 1281-1288.	0.7	17
153	Activation of YAP-1 by C-MYC Pathway is a Therapeutic Target in Hepatocellular Carcinoma under Hypoxic Condition. Journal of Hepatology, 2016, 64, S582-S583.	1.8	0
154	TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials. British Journal of Cancer, 2016, 115, 1201-1205.	2.9	19
155	Gadoxetic Acid Disodium-Enhanced MRI Combined Surveillance Improves Clinical Outcome by Sensitive Detection of Early Stage Hepatocellular Carcinoma, Compared with Ultrasonography Based Surveillance, in Patients with Cirrhosis. Journal of Hepatology, 2016, 64, S341-S342.	1.8	0
156	Percutaneous ethanol injection therapy is comparable to radiofrequency ablation in hepatocellular carcinoma smaller than 1.5 cm. Medicine (United States), 2016, 95, e4551.	0.4	13
157	Serum Tumor Markers Provide Refined Prognostication in Selecting Liver Transplantation Candidate for Hepatocellular Carcinoma Patients Beyond the Milan Criteria. Annals of Surgery, 2016, 263, 842-850.	2.1	105
158	Hypoxia Enhances Tumor-Stroma Crosstalk that Drives the Progression of Hepatocellular Carcinoma. Digestive Diseases and Sciences, 2016, 61, 2568-2577.	1.1	22
159	17β-estradiol exerts anticancer effects in anoikis-resistant hepatocellular carcinoma cell lines by targeting IL-6/STAT3 signaling. Biochemical and Biophysical Research Communications, 2016, 473, 1247-1254.	1.0	24
160	Characteristics of 1â€day postoperative mortality: a comparison with 2―to 7â€day postoperative mortality. Acta Anaesthesiologica Scandinavica, 2016, 60, 432-440.	0.7	3
161	Ultrasound assessment of gastric volume in children after drinking carbohydrate-containing fluids. British Journal of Anaesthesia, 2016, 116, 513-517.	1.5	40
162	Switching Monopolar Radiofrequency Ablation Using a Separable Cluster Electrode in Patients with Hepatocellular Carcinoma: A Prospective Study. PLoS ONE, 2016, 11, e0161980.	1,1	14

#	Article	IF	CITATIONS
163	Survival Analysis of Single Large (>5 cm) Hepatocellular Carcinoma Patients: BCLC A versus B. PLoS ONE, 2016, 11, e0165722.	1.1	33
164	Tenofovir-associated nephrotoxicity in patients with chronic hepatitis B: two cases. Clinical and Molecular Hepatology, 2016, 22, 286-291.	4.5	15
165	Combination of Pegylated Interferon and Nucleos(t)ide Therapy: Toward a Cure of Hepatitis B Virus Infection?. Gut and Liver, 2016, 10, 497-498.	1.4	1
166	Visceral Obesity Predicts Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Medicine (United States), 2015, 94, e2159.	0.4	85
167	JNK signaling in hepatocarcinoma cells is associated with the side population upon treatment with anticancer drugs. Molecular Medicine Reports, 2015, 11, 263-268.	1.1	4
168	P0325 : Every 3-month surveillance is superior to semiannual surveillance for the survival of patients with hepatocellular carcinoma after hepatectomy: A 10-year observational study. Journal of Hepatology, 2015, 62, S430-S431.	1.8	0
169	Comparison of the efficacies of entecavir 0.5 and 1.0 mg combined with adefovir in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analogue treatments. Journal of Medical Virology, 2015, 87, 999-1007.	2.5	0
170	Association of <i><scp>VARS</scp>2â€<scp>SFTA</scp>2</i> polymorphisms with the risk of chronic hepatitis B in a Korean population. Liver International, 2015, 35, 1934-1940.	1.9	21
171	Forns index predicts recurrence and death in patients with hepatitis Bâ€related hepatocellular carcinoma after curative resection. Liver International, 2015, 35, 1992-2000.	1.9	15
172	Efficacy of antiviral prophylaxis in <scp>HB</scp> sAgâ€negative, antiâ€ <scp>HB</scp> c positive patients undergoing hematopoietic stem cell transplantation. Liver International, 2015, 35, 2530-2536.	1.9	24
173	The Safety and Clinical Outcomes of Chemoembolization in Child-Pugh Class C Patients with Hepatocellular Carcinomas. Korean Journal of Radiology, 2015, 16, 1283.	1.5	12
174	Diagnostic and Prognostic Values of Noninvasive Predictors of Portal Hypertension in Patients with Alcoholic Cirrhosis. PLoS ONE, 2015, 10, e0133935.	1.1	36
175	Hepatitis B Virus-Related Glomerulonephritis: Not a Predominant Cause of Proteinuria in Korean Patients with Chronic Hepatitis B. Gastroenterology Research and Practice, 2015, 2015, 1-6.	0.7	4
176	Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma. Gastroenterology, 2015, 148, 1383-1391.e6.	0.6	371
177	Synergistic anti-tumor efficacy of doxorubicin and flavopiridol in an in vivo hepatocellular carcinoma model. Journal of Cancer Research and Clinical Oncology, 2015, 141, 2037-2045.	1.2	16
178	Hepatoprotective effect of vitamin C on lithocholic acid-induced cholestatic liver injury in Gulo(â^'/â^') mice. European Journal of Pharmacology, 2015, 762, 247-255.	1.7	16
179	Reply. Gastroenterology, 2015, 149, 1640-1641.	0.6	0
180	A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma. British Journal of Cancer, 2015, 113, 1666-1676.	2.9	73

#	Article	IF	CITATIONS
181	Fucoidan protects hepatocytes from apoptosis and inhibits invasion of hepatocellular carcinoma by up-regulating p42/44 MAPK-dependent NDRG-1/CAP43. Acta Pharmaceutica Sinica B, 2015, 5, 544-553.	5.7	36
182	Barcelona Clinic Liver Cancer staging system and survival of untreated hepatocellular carcinoma in a hepatitis B virus endemic area. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 696-705.	1.4	13
183	The effect of therapeutic vaccination for the treatment of chronic hepatitis B virus infection. Journal of Medical Virology, 2015, 87, 575-582.	2.5	14
184	Comparison of diagnostic methods for onychomycosis, and proposal of a diagnostic algorithm. Clinical and Experimental Dermatology, 2015, 40, 479-484.	0.6	52
185	P0637 : Short-term antiviral prophylaxis is not effective in HBsAg-negative, anti-HBc positive, and/or anti-HBs patients undergoing hematopoietic stem cell transplantation. Journal of Hepatology, 2015, 62, S557-S558.	1.8	0
186	Comparison of Transarterial Chemoembolization and Hepatic Resection for Large Solitary Hepatocellular Carcinoma: A Propensity Score Analysis. Journal of Vascular and Interventional Radiology, 2015, 26, 651-659.	0.2	32
187	Prediction of fluid responsiveness using a non-invasive cardiac output monitor in children undergoing cardiac surgery. British Journal of Anaesthesia, 2015, 115, 38-44.	1.5	27
188	Non-hypervascular hepatobiliary phase hypointense nodules on gadoxetic acid-enhanced MRI: Risk of HCC recurrence after radiofrequency ablation. Journal of Hepatology, 2015, 62, 1122-1130.	1.8	70
189	<scp>CLIF</scp> â€ <scp>SOFA</scp> scoring system accurately predicts shortâ€ŧerm mortality in acutely decompensated patients with alcoholic cirrhosis: a retrospective analysis. Liver International, 2015, 35, 46-57.	1.9	55
190	Tenofovir Monotherapy versus Tenofovir plus Lamivudine or Telbivudine Combination Therapy in Treatment of Lamivudine-Resistant Chronic Hepatitis B. Antimicrobial Agents and Chemotherapy, 2015, 59, 972-978.	1.4	20
191	Comparison of the Efficacy of Entecavir and Tenofovir in Nucleos(T)ide Analogue-Experienced Chronic Hepatitis B Patients. PLoS ONE, 2015, 10, e0130392.	1.1	8
192	Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea. Clinical and Molecular Hepatology, 2015, 21, 358.	4.5	12
193	Spontaneous Evolution in Bilirubin Levels Predicts Liver-Related Mortality in Patients with Alcoholic Hepatitis. PLoS ONE, 2014, 9, e100870.	1.1	18
194	Does 18F-FDG Positron Emission Tomography-Computed Tomography Have a Role in Initial Staging of Hepatocellular Carcinoma?. PLoS ONE, 2014, 9, e105679.	1.1	43
195	Does antiviral therapy reduce complications of cirrhosis?. World Journal of Gastroenterology, 2014, 20, 7306.	1.4	16
196	Telbivudine protects renal function in patients with chronic hepatitis <scp>B</scp> infection in conjunction with adefovirâ€based combination therapy. Journal of Viral Hepatitis, 2014, 21, 873-881.	1.0	24
197	Small Single-Nodule Hepatocellular Carcinoma: Comparison of Transarterial Chemoembolization, Radiofrequency Ablation, and Hepatic Resection by Using Inverse Probability Weighting. Radiology, 2014, 271, 909-918.	3.6	97
198	Nonalcoholic fatty liver disease is a negative risk factor for prostate cancer recurrence. Endocrine-Related Cancer, 2014, 21, 343-353.	1.6	20

#	Article	IF	CITATIONS
199	High-sensitivity C-reactive Protein Level is an Independent Predictor of Poor Prognosis in Cirrhotic Patients With Spontaneous Bacterial Peritonitis. Journal of Clinical Gastroenterology, 2014, 48, 444-449.	1.1	20
200	Prior Exposure to Lamivudine Increases Entecavir Resistance Risk in Chronic Hepatitis B Patients without Detectable Lamivudine Resistance. Antimicrobial Agents and Chemotherapy, 2014, 58, 1730-1737.	1.4	28
201	Generation of Humanized Liver Mouse Model by Transplant of Patient-Derived Fresh Human Hepatocytes. Transplantation Proceedings, 2014, 46, 1186-1190.	0.3	12
202	Sodium taurocholate cotransporting polypeptide mediates dual actions of deoxycholic acid in human hepatocellular carcinoma cells: enhanced apoptosis versus growth stimulation. Journal of Cancer Research and Clinical Oncology, 2014, 140, 133-144.	1.2	12
203	Repeated Intra-Arterial Therapy via the Cystic Artery for Hepatocellular Carcinoma. CardioVascular and Interventional Radiology, 2014, 37, 1283-1291.	0.9	7
204	Spontaneous fungal peritonitis: a severe complication in patients with advanced liver cirrhosis. European Journal of Clinical Microbiology and Infectious Diseases, 2014, 33, 259-264.	1.3	78
205	Association of a micro <scp>RNA</scp> â€323b polymorphism with the persistence of hepatitis <scp>B</scp> virus infection by the enhancement of viral replication. Journal of Viral Hepatitis, 2014, 21, 853-859.	1.0	17
206	Side population in <scp>LX2</scp> cells decreased by transforming growth factor‵². Hepatology Research, 2014, 44, 229-237.	1.8	4
207	Efficacy of Entecavir-Tenofovir Combination Therapy for Chronic Hepatitis B Patients with Multidrug-Resistant Strains. Antimicrobial Agents and Chemotherapy, 2014, 58, 6710-6716.	1.4	32
208	Tauroursodeoxycholic Acid Attenuates Progression of Steatohepatitis in Mice Fed a Methionine–Choline-Deficient Diet. Digestive Diseases and Sciences, 2014, 59, 1461-1474.	1.1	37
209	Relationship between polymorphisms near the <i><scp>IL</scp>28B</i> gene and spontaneous <scp>HB</scp> sAg seroclearance: a systematic review and metaâ€analysis. Journal of Viral Hepatitis, 2014, 21, 163-170.	1.0	16
210	Role of C-Arm CT in Identifying Caudate Arteries Supplying Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2014, 25, 1380-1388.	0.2	17
211	P445 CLIF-SOFA SCORING SYSTEM ACCURATELY PREDICTS IMMINENT MORTALITY OF ACUTELY DECOMPENSATED PATIENTS WITH ALCOHOLIC CIRRHOSIS. Journal of Hepatology, 2014, 60, S217.	1.8	Ο
212	Emphysematous phenotype is an independent predictor for frequent exacerbation of COPD. International Journal of Tuberculosis and Lung Disease, 2014, 18, 1407-1414.	0.6	30
213	Serum Insulin-Like Growth Factor-1 Predicts Disease Progression and Survival in Patients with Hepatocellular Carcinoma Who Undergo Transarterial Chemoembolization. PLoS ONE, 2014, 9, e90862.	1.1	11
214	Comparison of the Effects of Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma between Patients with and without Extrahepatic Metastases. PLoS ONE, 2014, 9, e113926.	1.1	17
215	A novel prognostic factor for hepatocellular carcinoma: protein disulfide isomerase. Korean Journal of Internal Medicine, 2014, 29, 580.	0.7	16
216	Survival of infiltrative hepatocellular carcinoma patients with preserved hepatic function after treatment with transarterial chemoembolization. Journal of Cancer Research and Clinical Oncology, 2013, 139, 635-643.	1.2	32

#	Article	IF	CITATIONS
217	Transarterial Chemoembolization with Additional Cisplatin Infusion for Hepatocellular Carcinoma Invading the Hepatic Vein. Journal of Vascular and Interventional Radiology, 2013, 24, 274-283.	0.2	42
218	The Efficacy of Adefovir Plus Entecavir Combination Therapy in Patients with Chronic Hepatitis B Refractory to Both Lamivudine and Adefovir. Digestive Diseases and Sciences, 2013, 58, 1363-1370.	1.1	6
219	39 GENOME-WIDE ASSOCIATION STUDY IDENTIFIES NEW VARIANTS ASSOCIATED WITH THE RISK OF CHRONIC HEPATITIS B. Journal of Hepatology, 2013, 58, S17.	1.8	0
220	Ventriculo-vascular coupling index in asymptomatic mild to moderate aortic stenosis: an important prognostic indicator. European Heart Journal, 2013, 34, P4725-P4725.	1.0	0
221	Hepatocellular Carcinoma: High Hepatitis B Viral Load and Mortality in Patients Treated with Transarterial Chemoembolization. Radiology, 2013, 267, 638-647.	3.6	28
222	A genome-wide association study identified new variants associated with the risk of chronic hepatitis B. Human Molecular Genetics, 2013, 22, 4233-4238.	1.4	105
223	Serum Insulin-like Growth Factor-I Level Is an Independent Predictor of Recurrence and Survival in Early Hepatocellular Carcinoma: A Prospective Cohort Study. Clinical Cancer Research, 2013, 19, 4218-4227.	3.2	28
224	Efficacy of Adefovir-Based Combination Therapy for Patients with Lamivudine- and Entecavir-Resistant Chronic Hepatitis B Virus Infection. Antimicrobial Agents and Chemotherapy, 2013, 57, 6325-6332.	1.4	13
225	Guggulsterone attenuates activation and survival of hepatic stellate cell by inhibiting nuclear factor kappa B activation and inducing apoptosis. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 1859-1868.	1.4	15
226	Polymorphisms nearInterleukin 28BGene Are Not Associated with Hepatitis B Virus Clearance, Hepatitis B e Antigen Clearance and Hepatocellular Carcinoma Occurrence. Intervirology, 2013, 56, 84-90.	1.2	27
227	Effect of remote ischaemic preconditioning on ischaemic–reperfusion injury in pulmonary hypertensive infants receiving ventricular septal defect repair. British Journal of Anaesthesia, 2012, 108, 223-228.	1.5	46
228	Simple Scoring System Predicting Genotypic Resistance During Rescue Therapy for Lamivudine-Resistant Chronic Hepatitis B. Journal of Clinical Gastroenterology, 2012, 46, 243-250.	1.1	4
229	1224 TAUROURSODEOXYCHOLIC ACID ATTENUATES HEPATIC FIBROSIS IN A MOUSE MODEL OF NON-ALCOHOLIC STEATOHEPATITIS. Journal of Hepatology, 2012, 56, S485.	1.8	0
230	Enhancement of hexokinase II inhibitor-induced apoptosis in hepatocellular carcinoma cells via augmenting ER stress and anti-angiogenesis by protein disulfide isomerase inhibition. Journal of Bioenergetics and Biomembranes, 2012, 44, 101-115.	1.0	39
231	Prognostic implications of tumor vascularity and its relationship to cytokeratin 19 expression in patients with hepatocellular carcinoma. Abdominal Imaging, 2012, 37, 439-446.	2.0	19
232	Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudineâ€resistant hepatitis B virus with or without adefovir resistance. Journal of Medical Virology, 2012, 84, 424-430.	2.5	16
233	Risk Factors, Clinical Features, and Prognosis of the Hepatocellular Carcinoma with Peritoneal Metastasis. Digestive Diseases and Sciences, 2012, 57, 813-819.	1.1	31
234	Association of Polymorphism in Pri-microRNAs-371-372-373 with the Occurrence of Hepatocellular Carcinoma in Hepatitis B Virus Infected Patients. PLoS ONE, 2012, 7, e41983.	1.1	23

#	Article	IF	CITATIONS
235	1262 GUGGULSTERONE INHIBITS LXRα MEDIATED SREBP-1C-DEPENDENT HEPATIC STEATOSIS THROUGH PKC DEPENDENT PATHWAY. Journal of Hepatology, 2011, 54, S498.	1.8	0
236	Mesalamineâ€induced B7â€H1 expression on hepatic stellate cells attenuates autoimmune liver injury. Hepatology Research, 2011, 41, 79-86.	1.8	4
237	848 COMPARISON OF NON-INVASIVE MARKERS OF FIBROSIS IN THE ASIAN NON-ALCOHOLIC FATTY LIVER DISEASE'S POPULATION WITH LOW PREVALENCE OF ADVANCED FIBROSIS. Journal of Hepatology, 2011, 54, S338-S339.	1.8	1
238	Validation of P2/MS and Other Noninvasive Fibrosis Scoring Systems in the Korean Population with Nonalcoholic Fatty Liver Disease. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2011, 57, 19.	0.2	10
239	Elevated Peripheral Blood Monocyte Fraction in Nonalcoholic Fatty Liver Disease. Tohoku Journal of Experimental Medicine, 2011, 223, 227-233.	0.5	15
240	Ursodeoxycholic acid-induced inhibition of DLC1 protein degradation leads to suppression of hepatocellular carcinoma cell growth. Oncology Reports, 2011, 25, 1739-46.	1.2	17
241	Why, When, and How to Prevent Hepatitis B Virus Reactivation in Cancer Patients Undergoing Chemotherapy. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 465-477.	2.3	24
242	Long-term Prognosis of Combined Hepatocellular and Cholangiocarcinoma After Curative Resection Comparison With Hepatocellular Carcinoma and Cholangiocarcinoma. Journal of Clinical Gastroenterology, 2011, 45, 69-75.	1.1	130
243	Negative hepatitis B envelope antigen predicts intrahepatic recurrence in hepatitis B virusâ€related hepatocellular carcinoma after ablation therapy. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 1638-1645.	1.4	17
244	Add-On Adefovir Is Superior to a Switch to Entecavir as Rescue Therapy for Lamivudine-Resistant Chronic Hepatitis B. Digestive Diseases and Sciences, 2011, 56, 2130-2136.	1.1	31
245	Protein induced by vitamin K absence or antagonist-II production is a strong predictive marker for extrahepatic metastases in early hepatocellular carcinoma: a prospective evaluation. BMC Cancer, 2011, 11, 435.	1.1	22
246	Transarterial Chemoembolization Can Be Safely Performed in Patients with Hepatocellular Carcinoma Invading the Main Portal Vein and May Improve the Overall Survival. Radiology, 2011, 258, 627-634.	3.6	264
247	Inhibition of hypoxia-inducible carbonic anhydrase-IX enhances hexokinase II inhibitor-induced hepatocellular carcinoma cell apoptosis. Acta Pharmacologica Sinica, 2011, 32, 912-920.	2.8	35
248	Human Cytomegalovirus Infection Causes Degradation of Sp100 Proteins That Suppress Viral Gene Expression. Journal of Virology, 2011, 85, 11928-11937.	1.5	77
249	Relative Etiological Role of Prior Hepatitis B Virus Infection and Nonalcoholic Fatty Liver Disease in the Development of Non-B Non-C Hepatocellular Carcinoma in a Hepatitis B-Endemic Area. Digestion, 2011, 84, 17-22.	1.2	57
250	Predictors of HBsAg Seroclearance in HBeAg-Negative Chronic Hepatitis B Patients. Digestion, 2011, 84, 23-28.	1.2	13
251	Metastatic hepatocellular carcinoma presenting as facial nerve palsy and facial pain. The Korean Journal of Hepatology, 2011, 17, 319.	1.5	4
252	Low P2/MS value is an independent risk factor for early recurrence of hepatocellular carcinoma after radiofrequency ablation therapy. Hepato-Gastroenterology, 2011, 58, 147-52.	0.5	2

#	Article	IF	CITATIONS
253	Caudate Lobe Hepatocellular Carcinoma Treated with Selective Chemoembolization. Radiology, 2010, 257, 278-287.	3.6	32
254	Identification of a Cholangiocarcinoma-Like Gene Expression Trait in Hepatocellular Carcinoma. Cancer Research, 2010, 70, 3034-3041.	0.4	166
255	Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease. Digestive and Liver Disease, 2010, 42, 503-508.	0.4	896
256	Retinoic acid and its binding protein modulate apoptotic signals in hypoxic hepatocellular carcinoma cells. Cancer Letters, 2010, 295, 229-235.	3.2	11
257	Hypoxia and retinoic acid-inducible NDRG1 expression is responsible for doxorubicin and retinoic acid resistance in hepatocellular carcinoma cells. Cancer Letters, 2010, 298, 9-15.	3.2	49
258	Validation of P2/MS for reflecting hepatic fibrosis in patients with hepatocellular carcinoma. The Korean Journal of Hepatology, 2010, 16, 389.	1.5	2
259	Development of Spontaneous Bacterial Peritonitis after Extended Hepatic Resection in a Patient without Evidence of Liver Cirrhosis. Gut and Liver, 2010, 4, 129-134.	1.4	0
260	Comparison of the bedside central venous catheter placement techniques: landmark vs electrocardiogram guidance. British Journal of Anaesthesia, 2009, 102, 662-666.	1.5	52
261	Enterococcus: not an innocent bystander in cirrhotic patients with spontaneous bacterial peritonitis. European Journal of Clinical Microbiology and Infectious Diseases, 2009, 28, 21-26.	1.3	18
262	Complete blood count reflects the degree of oesophageal varices and liver fibrosis in virusâ€related chronic liver disease patients. Journal of Viral Hepatitis, 2009, 16, 444-452.	1.0	21
263	Enhanced interleukin-2 diphtheria toxin conjugate-induced growth suppression in retinoic acid-treated hypoxic hepatocellular carcinoma cells. Cancer Letters, 2009, 274, 259-265.	3.2	6
264	Hypoxia-inducible adrenomedullin accelerates hepatocellular carcinoma cell growth. Cancer Letters, 2008, 271, 314-322.	3.2	27
265	Evaluation of corrected flow time in oesophageal Doppler as a predictor of fluid responsiveness. British Journal of Anaesthesia, 2007, 99, 343-348.	1.5	96
266	Wnt signaling enhances the activation and survival of human hepatic stellate cells. FEBS Letters, 2007, 581, 2954-2958.	1.3	77
267	Hepatic intra-arterial injection of 3-bromopyruvate in rabbit vx2 tumor. Acta Radiologica, 2006, 47, 1036-1041.	0.5	6
268	Decompression of the spinal subarachnoid space as a solution for syringomyelia without Chiari malformation. Spinal Cord, 2002, 40, 501-506.	0.9	48
269	Expression of the CD44 adhesion molecule in primary and metastatic gynecologic malignancies and their cell lines. International Journal of Gynecological Cancer, 1995, 5, 193-199.	1.2	11